SYT13 and metastatic malignant neoplasm in the lymph nodes: Furthermore, no significant differences were found between T1 (n = 154) and T2/T3/T4 (n = 378; p = 0.849), lymph node metastasis-positive (n = 237) and negative (n = 292; p = 0.352), or stage I/II (n = 401) and stage III/IV (n = 128; p = 0.621) in SYT13 mRNA expression levels in ER-positive patients (n = 532); the finding is consistent with the results of our clinical samples.